OncoMatch/Clinical Trials/NCT06417008
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
Is NCT06417008 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including HS-20117 and Aumolertinib for non-squamous non-small cell lung cancer.
Treatment: HS-20117 · Aumolertinib — HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of this study is to assess the safety, efficacy, pharmacokinetics and immunogenicity of HS-20117 combined with Aumolertinib in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions \[Exon 19del\] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR sensitizing mutation
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: MET inhibitor
Previous or current treatment with MET targeted therapy
Cannot have received: EGFR-targeted antibody
Previous or current treatment with EGFR targeted antibodies
Cannot have received: antibody-drug conjugate
Previous or current treatment with antibody-drug conjugates (ADC)
Cannot have received: traditional Chinese medicine indicated for tumors
Traditional Chinese medicine indicated for tumors
Cannot have received: major surgery or other local therapy
major surgery or other local therapy within washout period to the first dose of study drug
Cannot have received: other investigational non-anti-tumor drugs
Other investigational non-anti-tumor drugs within the washout period
Lab requirements
Blood counts
Inadequate bone marrow reserve [excluded]
Kidney function
Inadequate organ functions [excluded]
Liver function
Inadequate organ functions [excluded]
Cardiac function
Severe, uncontrolled or active cardiovascular disorders [excluded]
Inadequate bone marrow reserve or organ functions. Severe, uncontrolled or active cardiovascular disorders.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify